Nebivolol Hydrochloride [3.30] — Mechanism, Dosage, Safety & Indian Brands

1. Clinical & Scientific Overview

Nebivolol Hydrochloride (TIP-MED-000030, Reference Code [3.30]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Cardioselective Beta-1 Blocker with Endothelial Nitric Oxide (NO)-Mediated Vasodilation (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.30], p. 35): Nebicard (Torrent), Nebistar (Lupin), Nodon (Cadila) — Strengths & Dosage Forms: Tablets: 2.5 mg, 5 mg, 10 mg; FDCs with Telmisartan (40/5 mg), Amlodipine (5/5 mg), or Cilnidipine (10/5 mg)

Representative Indian Market Examples (Edition 2.7 Ch 03 [3.30], p. 35): Nebicard (Torrent), Nebistar (Lupin), Nodon (Cadila) — Strengths & Dosage Forms: Tablets: 2.5 mg, 5 mg, 10 mg; FDCs with Telmisartan (40/5 mg), Amlodipine (5/5 mg), or Cilnidipine (10/5 mg)

Dosage Forms & Available Strengths:
Tablets: 2.5 mg, 5 mg, 10 mg; FDCs with Telmisartan (40/5 mg), Amlodipine (5/5 mg), or Cilnidipine (10/5 mg)

Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Cardioselective Beta-1 Blocker with Endothelial Nitric Oxide (NO)-Mediated Vasodilation (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Cardioselective Beta-1 Blocker with Endothelial Nitric Oxide (NO)-Mediated Vasodilation (Schedule H) for Essential hypertension, chronic heart failure in older adults (>=70 years, SENIORS trial), CAD with metabolic syndrome or mild COPD.

4. Therapeutic Indications & Evidence-Supported Uses

Essential hypertension, chronic heart failure in older adults (>=70 years, SENIORS trial), CAD with metabolic syndrome or mild COPD

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: HTN: 5 mg PO OD (start 2.5 mg OD in elderly or CKD; max 10 mg OD). Heart Failure: Start 1.25 mg OD, titrate every 1–2 weeks to max 10 mg OD

Administration & Meal Timing: May be taken with or without food at the same time each morning | Morning (Once Daily)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

Metabolism & Biotransformation:
Renal: Start at 2.5 mg OD if eGFR <30 mL/min (max 5 mg OD). Hepatic: Contraindicated in moderate-to-severe hepatic impairment

Elimination & Renal Adjustment:
Renal: Start at 2.5 mg OD if eGFR <30 mL/min (max 5 mg OD). Hepatic: Contraindicated in moderate-to-severe hepatic impairment

Hepatic Impairment Considerations:
Renal: Start at 2.5 mg OD if eGFR <30 mL/min (max 5 mg OD). Hepatic: Contraindicated in moderate-to-severe hepatic impairment

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:

Contraindicated in severe bradycardia (<50 bpm), 2nd/3rd-degree heart block, cardiogenic shock, decompensated HF, severe asthma, and Child–Pugh B/C hepatic impairment

Key Clinical Precautions: Renal: Start at 2.5 mg OD if eGFR <30 mL/min (max 5 mg OD). Hepatic: Contraindicated in moderate-to-severe hepatic impairment

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:

Mild bradycardia, headache, fatigue, dizziness (lower rates of erectile dysfunction and metabolic glucose/lipid worsening than Atenolol)
Severe bradycardia, heart block, bronchospasm (at doses >10 mg where beta-1 selectivity diminishes), masking of hypoglycaemic tachycardia

Serious / Dose-Limiting Adverse Effects:

Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

CYP2D6 inhibitors (Fluoxetine, Paroxetine, Bupropion) increase Nebivolol levels 3–4-fold; additive bradycardia with Diltiazem, Verapamil, Digoxin, Amiodarone, or Ivabradine

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

Patient Counselling Checklist: Do not stop tablets suddenly (risk of rebound angina/BP surge); diabetic patients should note that sweating remains an intact warning sign of low sugar
Meal & Clock Timing Instruction: May be taken with or without food at the same time each morning (Morning (Once Daily))
Missed Dose Protocol: Take same day if remembered; skip if next day; never stop suddenly
Geriatric Dispensing Pearl: Well-validated in elderly HF (start 1.25–2.5 mg OD); monitor for bradycardia (<55 bpm)

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 2.5 mg, 5 mg, 10 mg; FDCs with Telmisartan (40/5 mg), Amlodipine (5/5 mg), or Cilnidipine (10/5 mg)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.30] (p. 35)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

13. Related Reference Monographs, Educational Guides & Visual Concept

💊 Related Pharmacological / Category Profiles

[3.32] Labetalol Hydrochloride — Combined Alpha-1 Selective & Non-Selective Beta Adrenoceptor Bloc
[3.33] Prazosin Hydrochloride (Extended-Release GITS) — Selective Postsynaptic Alpha-1 Adrenoceptor Blocker (Schedule H)
[3.34] Clonidine Hydrochloride — Central Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Sche
[3.35] Methyldopa — Centrally Acting Alpha-2 Adrenoceptor Agonist Prodrug (Schedule H

📚 Related Knowledge Hub Educational Articles

Receptor Pharmacodynamics & Mechanism of Action Illustration

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback